Abstract
Objective
To evaluate the response and the side effects of Iressa on the first line treatment in senium advanced stage non-small cell lung cancer.
Methods
Sixteen non-small cell lung cancer patients were observed from November 2005 to September 2007, the date of patients belong to the Second Affiliated Hospital of Dalian Medical University. I was prescribed on the first line at oral dose of 250 mg daily as a continuous dose. Then the response and side-effects of Iressa were evaluated.
Results
Among 16 patients, CR, PR, SD, PD were 0% (0/16), 37.5% (6/16), 50% (8/16), 12.5% (2/16) respectively. CR + PR + SD was 87.5% (14/16). Adverse events: rash 37.5% (6/16), dry skin 18.75% (3/16), itching of skin 12.5% (2/16), diarrhea 31.25 (5/16), and hepatic dysfunction (GPT increase) 12.5% (2/16).
Conclusion
Iressa is active on the first line treatment in old age advanced stage non-small cell lung cancer. It is well tolerated with adverse events. The quality of life may be improved significantly.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366: 1527–1537.
Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in Patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol, 2006, 1: 847–855.
Zhang L, Yu SY. Gefitinib in the treatment of advanced non-small-cell lung cancer. Chin J Oncol (Chinese), 2006, 28: 539–541.
Mu XL, Li LY, Zhang XT, et al. Evaluation of safety and efficacy of gefitinib (Iressa, ZD1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme. BMC Cancer, 2004, 4: 51–59.
Zhang Y, Chen L, Zhang PL, et al. Gefitinib in treatment of refractory non-small cell lung cancer. Chin J New Drugs Clin Rem (Chinese), 2006, 25: 196–199.
Park K, Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin, 2006, 22: 561–573.
The Chinese edition of NCCN clinical practice guidelines in oncology-non-small cell lung Cancer Guideline, 2007: NSCL-15.
Li Y, Zhang XR, Sun Y. Advances of targeted therapy in the treatment of non-small cell lung cancer. Oncol Prog (Chinese), 2007, 5: 151–157.
Wang HJ, Zhang XR. EGFR inhibitor treats the non-cellule lung cancer new progress. Oncol Prog (Chinese), 2005, 3: 80–84.
Niho S, Kubota K, Goto K, et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol, 2006, 24: 64–69.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sun, X., Zhang, Y., Zhang, X. et al. The clinical evaluation of Iressa first-line treatment of senium advanced-stage non-small cell lung cancer. Chin. -Ger. J. Clin. Oncol. 7, 203–206 (2008). https://doi.org/10.1007/s10330-008-0016-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10330-008-0016-0